Food and Drug Administration (FDA) database from 2004 to 2009 reported increased risks of pancreatic and thyroid cancer associated with the GLP-1 receptor agonist (GLP-1RA) exenatide compared to other therapies [8]
Those in the semaglutide treatment group experienced about 11% greater weight loss than the placebo group, reduced inflammation, and improved physical limitations
Retrieved from Bengtson, A
Clinically, it is considered among the least concerning for long-term use
When used at the recommended dose and combined with lifestyle changes, they can lead to significant weight loss and improved health
With the right knowledge, the right tools (such as quality insulin syringes), and a conscientious approach, retatrutide can be used safely in a research context